Regeneron Reports Second Quarter 2019 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Regeneron (REGN) Tops Q2 EPS by 61c, Revenues Beat
August 6, 2019 6:43 AM EDTRegeneron (NASDAQ: REGN) reported Q2 EPS of $6.02, $0.61 better than the analyst estimate of $5.41. Revenue for the quarter came in at $1.93 billion versus the consensus estimate of $1.8 billion.
Second quarter 2019 revenues increased 20% to $1.93 billion versus second quarter 2018EYLEA® U.S. net sales increased 17% to $1.16 billion versus second quarter 2018Dupixent® global net sales, which are recorded by the Company's collaborator Sanofi, increased 166% to $557... More